HomepageTWST • NASDAQ
add
Twist Bioscience Corp
Vorige slotkoers
$ 52,88
Dag-range
$ 52,48 - $ 57,88
Jaar-range
$ 23,30 - $ 57,88
Beurswaarde
3,51 mld. USD
Gem. volume
1,52 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 103,70 mln. | 16,89% |
Bedrijfskosten | 86,87 mln. | 12,12% |
Netto inkomsten | -30,51 mln. | 3,44% |
Netto winstmarge | -29,42 | 17,38% |
Winst per aandeel | -0,50 | 5,66% |
EBITDA | -27,01 mln. | 5,45% |
Effectief belastingtarief | -0,84% | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 197,95 mln. | -26,91% |
Totale activa | 638,08 mln. | 4,85% |
Totale passiva | 181,99 mln. | 19,23% |
Totaal aandelenvermogen | 456,10 mln. | — |
Uitstaande aandelen | 61,31 mln. | — |
Koers-boekwaardeverhouding | 7,11 | — |
Rendement op activa | -12,85% | — |
Rendement op kapitaal | -14,52% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -30,51 mln. | 3,44% |
Operationele kasstroom | -24,81 mln. | -15,80% |
Kasstroom uit beleggingen | -9,93 mln. | -546,68% |
Kasstroom uit financiering | 298,00K | -98,34% |
Nettomutatie in liquide middelen | -34,44 mln. | -578,89% |
Vrije kasstroom | -25,86 mln. | -130,04% |
Over
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Opgericht
2013
Website
Werknemers
979
